ACT News 214.26 08/01/2014 04:24:39 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 214.26 $ACT

Many Leading Stocks Damaged As Market Tumbles Broadly
at Investor's Business Daily - Thu Jul 31, 1:51PM CDT
The stock market remained sharply lower in afternoon trading, a sell-off worsened by the many leading stocks coming under attack. The Nasdaq tumbled 1.6%, the S&P 500 1.4% and the Dow Jones industrial average 1.3%. The small-cap Russell 2000 skidded...

3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.

Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 1:38PM CDT
The trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. Mutual funds holding these stocks in their portfolio should thus experience solid uplift in the near term.

Actavis May Give Buyers Another Chance
at Investor's Business Daily - Mon Jul 28, 5:03PM CDT
Drugmaker Actavis broke out of a cup-with-handle base June 18 but hasn't made much headway since then. It's slightly below a 216.80 buy point, struggling for support at its 50-day moving average. But it might be building a new handle and could make...

Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?
Brian Nichols, The Motley Fool - Motley Fool - Thu Jul 24, 7:54AM CDT
UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals , a company that UBS believes will benefit from continued patent...

Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook

Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews

World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Medicines360 and Actavis files Levosert IUD's NDA for US FDA's substantive review
M2 - Tue Jul 22, 8:15AM CDT
Pharmaceutical company Medicines360 disclosed on Monday that the US Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for Levosert in partnershp with Actavis (NYSE:ACT).

Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert(TM) IUD
PR Newswire - Mon Jul 21, 3:30PM CDT
Medicines360, a non-profit women's health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's New Drug Application (NDA) for Levosert(TM) (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy.

Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 5:15PM CDT
Synergy Pharmaceuticals (SGYP) completed patient enrollment for its phase II study on SP-333.

Enable Partners, Other Leaders Facing Market Pressure
at Investor's Business Daily - Fri Jul 18, 5:10PM CDT
When the market is under pressure, stocks often face a tougher time following through on breakouts, and this time around is no exception. Actavis (ACT), Concho Resources (CXO) and Enable Midstream Partners (ENBL) are among leading Spotlight stocks...

Glance: Biggest corporate deals so far this year
By The Associated Press - AP - Fri Jul 18, 10:58AM CDT
Abbvie Inc.'s deal to combine with Shire PLC would be the largest made so far this year, excluding assumed debt. Here are the top five:

Mylan (MYL) Joins the Tax-Inversion Wave - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Jul 16, 12:03PM CDT
More M&A activity involving tax-inversion can be expected in the days ahead.

Facebook, Apple Suppliers Lead 5 Big-Cap All-Stars
at Investor's Business Daily - Wed Jul 16, 8:16AM CDT
Looking for Wall Street's stock all-stars? IBD's Screen of the Day is Big Cap Leaders, which includes the top-performing large-cap stocks with strong fundamentals and technicals. This article focuses on the screen's five companies including social...

Mylan to Buy Abbott Generic Drug Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:10PM CDT
Mylan (MYL) will buy Abbott's (ABT) non-U.S. developed markets specialty and branded generics business.

Actavis Fuels Growth With Acquisitions, New Generics
at Investor's Business Daily - Mon Jul 14, 4:30PM CDT
Actavis (ACT) has kept busy on the merger and acquisition trail the past couple of years. Since closing its acquisition of Forest Laboratories on July 2, when new CEO (and former Forest chief) Brenton Saunders took the helm, Actavis has completed a...

Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Mylan Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS) and Hospira, Inc. (NYSE: HSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4724-100free.

Actavis Confirms Generic Diclegis® Patent Challenge
PR Newswire - Fri Jul 11, 3:25PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis®, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 151

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 124

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 24

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 129

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 0

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 113

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 149

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 178

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading

Top 5 Most Recently Viewed Articles

Hank Cherry Secures Victory at the Bassmaster Elite Championship

Updated Category News Views 220

Hank Cherry Secures Victory at the Bassmaster Elite Championship Hank Cherry, celebrating his 52nd birthday, showcased an impressive fishing technique that led him to victory at the FXR Bassmaster Elite event held at Lake Guntersville. With an astonishing four-day total of 88 pounds, 11 ounces, Cherry emerged triumphant, demonstrating a remarkable blend of skill and...

Continue Reading
Introducing trans-ASC: Boost Your Meta Advertising Results

Updated Category News Views 149

transcosmos Unveils Revolutionary Advertising Solution In a significant move, transcosmos has introduced an innovative advertising solution known as "trans-ASC." This tool is designed to help businesses enhance their advertising efforts through precise targeting, utilizing the Advantage+ sales campaigns developed by Meta Platforms, Inc. By streamlining the process,...

Continue Reading
VCI Global's New $5 Million Direct Offering Strategy Unveiled

Updated Category News Views 203

VCI Global Announces Significant Direct Offering VCI Global Limited (NASDAQ: VCIG), a prominent player in business and technology consulting, has revealed an exciting new agreement that marks a pivotal moment for the company. This initiative involves a registered direct offering where VCI Global will sell approximately 2,777,778 ordinary shares at a price of $1.80 per...

Continue Reading
Dev Technosys Recognized Among Premier Mobile App Developers

Updated Category News Views 181

Dev Technosys Secures a Top Spot in Mobile App Development Dev Technosys has recently announced its ranking among the premier mobile app development companies in a published global list. The surge in demand for mobile app solutions has propelled the company into this prestigious ranking, showcasing its competitive edge in the ever-growing mobile app market. Currently...

Continue Reading
Pulmonx Corporation to Showcase Innovations at Key Medtech Event

Updated Category News Views 119

Pulmonx Corporation Set to Shine at Major Medtech Gathering Pulmonx Corporation, recognized as a global leader in minimally invasive treatments for severe lung diseases, is excited to announce its upcoming participation in the Citi 2025 Unplugged Medtech and Life Sciences Access Day. This significant event is scheduled to take place in New York, providing a great platform...

Continue Reading